Tag: COSMIC-311

Home / COSMIC-311

Categories

Cabozantinib is approved for differentiated thyroid cancer

October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age and older who have locally advanced or me...
cosmic-311

Scan the code